Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma
  • CME

Credits Available
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: January 27, 2022 Expiration: January 26, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Oncopeptides
Pfizer, Inc.
Sanofi Genzyme
Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesus San-Miguel, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis, staging criteria, and risk factors
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data, as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Appraise the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as response to and tolerance of previous therapies
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials
  • Manage adverse events related to newer therapies used in the treatment of multiple myeloma to ensure optimal clinical benefit from treatment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees for non-CME/CE services from Amgen.

Faculty

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director,
Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received funds for research support from Amgen, Johnson & Johnson/Janssen, Sanofi, and Seattle Genetics and consulting funds from GlaxoSmithKline and Oncopeptides.
Philippe Moreau, MD

Professor of Clinical Hematology
Head,
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, Oncopeptides, and Sanofi.
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no relevant conflicts of interest to report.
Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio, and Takeda.

Staff

Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Goal

The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 27, 2022, through January 26, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma
  • CME

Loading...
Watch this on-demand webcast of a live CCO symposium where renowned clinical experts discuss patient case studies and key clinical trial data, providing their perspectives on recent advances in the treatment of multiple myeloma, including a new treatment algorithm for 2022.
Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesus San-Miguel, MD, PhD
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: January 27, 2022 Expiration: January 26, 2023

Related Content

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director
Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD
Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

On-demand webcast from a CAP satellite symposium on the role of pathology in myelodysplastic syndromes, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Alexa J. Siddon, MD Cecilia Yeung, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point ABPath MOC: maximum of 1.0 Lifelong Learning point Released: November 29, 2022 Expired: November 28, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Oncopeptides
Pfizer, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings